In Brief: Adeza Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Adeza Biomedical: Gains approval from FDA to market its fetal fibronectin immunoassay test as an aid in detecting preterm delivery in asymptomatic women. The test originally was approved in September 1995 for use with symptomatic women ("The Gray Sheet" Oct. 2, 1995, p. 4). Matria Healthcare has exclusive U.S. marketing rights to the test...